Canopy Growth has stabilized its balance sheet and rebuilt around medical cannabis, but profitability, dilution, and accounting-control failures keep the turnaround firmly in “prove it” territory.
Overview
Canopy Growth’s FY2026 results show a company in transition: revenue returned to growth, medical cannabis momentum accelerated, and a major recapitalization shifted the balance sheet to net cash. However, Q4 earnings missed badly due to write-offs, GAAP losses remain substantial, Storz & Bickel weakened, and financial restatements exposed ineffective internal controls. The report maintains a neutral Hold view: Canopy has improved liquidity and attractive medical cannabis positions, but governance, dilution, profitability, and execution risks still prevent a more constructive investment stance.